In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Heron Therapeutics (NASDAQ: HRTX), with a price target of $54. The company’s shares opened today at $39, close to its 52-week high of $42.05.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 16.9% and a 53.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.
Currently, the analyst consensus on Heron Therapeutics is Strong Buy and the average price target is $44.25, representing a 13.5% upside.
In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $40 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $42.05 and a one-year low of $12.70. Currently, Heron Therapeutics has an average volume of 1.12M.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HRTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011.
